# Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

> **NCT01854645** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 2103 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** GFF MDI
- **DRUG:** GP MDI
- **DRUG:** FF MDI
- **DRUG:** Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
- **DRUG:** Placebo MDI

## Key facts

- **NCT ID:** NCT01854645
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 2103 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854645, "Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01854645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*